2022 Drug Safety Communications
- FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib) 6/30/2022
- FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns 6/1/2022
- FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging 3/30/2022
- FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib) 2/3/2022
- FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 1/12/2022